In summary, this study identifies a critical epigenetic regulatory axis in NASH progression and we also present this NF-κB-MLL4 axis as a potential target for anti-NASH drug development. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.